Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100561 | 1.00 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL27691305 | 1.00 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL23112809 | 1.00 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL27924785 | 0.97 | LMNA (0.65) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL27943599 | 0.97 | LMNA (0.65) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL1263924 | 0.97 | LMNA (0.63) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL93604 | 0.97 | LMNA (0.63) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL6557927 | 0.97 | LMNA (0.63) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL27320996 | 0.94 | LMNA (0.60) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL8945113 | 0.92 | LMNA (0.63) | LMNABLMMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137756-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION (US) | 2024-06-27 | — | — | WO | claimed |
| US-20240180932-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | NESTLE SA (CH) | 2024-06-06 | — | — | US | claimed |
| EP-4313017-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | Société des Produits Nestlé S.A. (CH) | 2024-02-07 | — | — | EP | claimed |
| US-20240010589-A1 | SUBSTITUTED RESORCINOL COMPOUNDS AS AMPK ACTIVATORS, COMPOSITIONS, METHODS AND USES THEREOF | NESTLE SA (CH) | 2024-01-11 | — | — | US | claimed |
| US-20230414638-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF | NESTLE SA (CH) | 2023-12-28 | — | — | US | claimed |
| WO-2023213715-A1 | AMPK ACTIVATOR (CBDA) AND SGLT2 INHIBITOR FOR METABOLIC HEALTH | Société des Produits Nestlé S.A. (CH) | 2023-11-09 | — | — | WO | claimed |
| CN-116981452-A | Substituted resorcinol compounds for the management of aging and related disorders | 雀巢产品有限公司 | 2023-10-31 | — | — | CN | claimed |
| EP-4247359-A1 | SUBSTITUTED RESORCINOL COMPOUNDS AS AMPK ACTIVATORS, COMPOSITIONS, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2023-09-27 | — | — | EP | claimed |
| CN-116761791-A | Substituted resorcinol compounds as AMPK activators and uses thereof | 雀巢产品有限公司 | 2023-09-15 | — | — | CN | claimed |
| EP-4240342-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2023-09-13 | — | — | EP | claimed |
| US-5245070-A | Alkyl phosphates having a branched alkyl group | FUJI PHOTO FILM CO., LTD. (JP) | 1993-09-14 | — | — | US | claimed |
| US-4980371-A | TREATMENT OF HIV INFECTIONS/LEUKEMIA; ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS | MERRELL DOW PHARMACEUTICALS (US) | 1990-12-25 | — | — | US | claimed |
| EP-0374886-A2 | Antiretroviral furan ketones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-27 | — | — | EP | claimed |
| EP-0353953-A2 | Performing an enzyme-catalysed reaction | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-07 | — | — | EP | claimed |
| US-4853156-A | Process for the manufacture of quinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 1989-08-01 | — | — | US | claimed |
| EP-0154977-B1 | GLYCERIN-ETHER PHOSPHATIDES, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-05-17 | — | — | EP | claimed |
| US-4694084-A | Glycerol ether phosphatides | HOFFMANN-LA ROCHE INC. (US) | 1987-09-15 | — | — | US | claimed |
| EP-0154977-A2 | Glycerin-ether phosphatides, their preparation and use | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-09-18 | — | — | EP | claimed |
| US-4264577-A | ALKYL OR ALKYLENE SULFATE IN SILICONE RUBBER MATRIX FOR UTERINE INSERTION | ELI LILLY AND COMPANY (US) | 1981-04-28 | — | — | US | claimed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414638-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF | PRKAG2, PRKAB2, PRKAG1 | LMNA 4223/4885BLM 4734/4885MEN1 3795/4885 |
| US-20240010589-A1 | SUBSTITUTED RESORCINOL COMPOUNDS AS AMPK ACTIVATORS, COMPOSITIONS, METHODS AND USES THEREOF | PRKAG2, PRKAG1, PRKAB2 | LMNA 2081/4885BLM 2311/4885MEN1 3057/4885 |
| US-20240180932-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | HSPA9, CS, SQSTM1 | LMNA 2758/4885BLM 1858/4885MEN1 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.